OOGENESIS: Development and Maturation of the Female Gamete Across the Lifespan
Oogenesis is the process through which female gametes (oocytes) develop, mature and ultimately become capable of fertilisation. Unlike spermatogenesis—which occurs continuously throughout adult life—oogenesis is unique in that the entire pool of oocytes is established before birth. These cells then undergo prolonged periods of arrest, with only a small number completing their development during the reproductive years.
This prolonged, stepwise process makes oogenesis one of the most complex and tightly regulated developmental pathways in human biology. It spans fetal development, puberty, the reproductive years and ultimately ends with menopause. Understanding oogenesis provides the foundation for interpreting fertility, chromosomal abnormalities, developmental disorders and age-related reproductive decline.
What You Need to Know
Oogenesis is the process by which female gametes are formed and matured, and it differs fundamentally from sperm production in both timing and capacity. It begins during fetal life, long before birth, when primordial germ cells migrate to the developing ovaries and differentiate into oogonia. These cells proliferate by mitosis until mid-gestation, after which they enter meiosis and become primary oocytes. At this point, oogenesis pauses, establishing a finite pool of oocytes that must last throughout the reproductive lifespan.
Each primary oocyte becomes arrested in prophase I of meiosis, a suspended state that may persist for decades. From birth onwards, no new oocytes are formed, and the total number steadily declines through atresia. This prolonged arrest is a defining feature of female reproductive biology and has important implications for fertility, ageing, and genetic integrity. Only a small fraction of the original oocyte population will ever resume meiosis and reach ovulation.
From puberty, cyclical hormonal signalling allows small numbers of primary oocytes to resume development within growing ovarian follicles. During each menstrual cycle, a cohort of follicles is recruited, but usually only one oocyte completes maturation and is released. Key stages in oocyte maturation include:
Completion of meiosis I, just before ovulation, producing a secondary oocyte and a first polar body
Entry into meiosis II, followed by arrest at metaphase II, the stage at which ovulation occurs
Completion of meiosis II only if fertilisation occurs, resulting in formation of the mature ovum and a second polar body
This tightly regulated, stepwise progression ensures that oocyte maturation is synchronised with ovulation and potential fertilisation. The dependence of oogenesis on long-term meiotic arrest, hormonal regulation, and selective recruitment underpins both normal reproductive function and many clinical patterns of infertility.
Beyond the Basics
Fetal Development and Establishment of the Oocyte Pool
Oogenesis begins early in fetal life, and the size of the oocyte pool is determined before birth. Primordial germ cells proliferate rapidly to form millions of oogonia, but this peak number is short-lived. As fetal development progresses, oogonia initiate meiosis and differentiate into primary oocytes, a transition that is accompanied by substantial attrition. Atresia occurs continuously during this period, so that by birth the ovarian reserve has already declined to approximately 1 to 2 million primary oocytes.
After birth, no new oocytes are generated in humans. Oocyte loss continues throughout childhood, even in the absence of cyclical hormonal stimulation. By the onset of puberty, the ovarian reserve has fallen to roughly 300,000 to 500,000 oocytes, setting the upper limit for reproductive lifespan. This progressive depletion explains why fertility is finite and why reproductive ageing is inevitable, even in the absence of overt pathology.
Meiotic Arrest and Follicular Cell Support
Primary oocytes remain arrested in prophase I of meiosis for many years, sometimes decades. This prolonged arrest is actively maintained rather than passive. Granulosa cells surrounding the oocyte play a central role by transmitting inhibitory signals, including cyclic AMP, through gap junctions that span the oocyte–granulosa cell interface. These signals prevent premature meiotic progression and support long-term oocyte viability.
As follicles grow, granulosa and theca cells become increasingly specialised, coordinating nutrient delivery, steroid hormone production, and structural integrity of the follicle. This tightly regulated microenvironment allows the oocyte to remain metabolically active while genetically stable. Disruption of follicular support, whether through endocrine imbalance, metabolic stress, or cytotoxic injury, typically leads to follicular atresia rather than successful maturation.
Resumption of Meiosis and Ovulatory Maturation
During each menstrual cycle, rising follicle-stimulating hormone recruits a cohort of antral follicles, but only one usually progresses to ovulation. In the dominant follicle, luteinising hormone triggers resumption of meiosis I shortly before ovulation. This division produces a secondary oocyte and a first polar body, which contains excess genetic material and minimal cytoplasm.
The secondary oocyte immediately enters meiosis II and arrests again, this time at metaphase II. This arrest positions the oocyte in a state of readiness for fertilisation. Completion of meiosis II occurs only after sperm penetration of the zona pellucida, ensuring that full chromosomal separation happens only when fertilisation is imminent. This timing is critical for maintaining genetic integrity while aligning oocyte maturation with reproductive opportunity.
Asymmetrical Division and Cytoplasmic Investment
A defining feature of oogenesis is its asymmetrical pattern of cell division. Rather than producing multiple equivalent gametes, oogenesis yields a single large oocyte and up to three polar bodies. This unequal division allows the oocyte to retain the vast majority of cytoplasm, organelles, and metabolic substrates required to support early embryonic development.
The ovum’s cytoplasmic reserves include mitochondria, messenger RNA, proteins, and nutrients that sustain the embryo during the earliest stages of development, before implantation and placental support are established. This strategy prioritises developmental competence over quantity, reflecting the high energetic and biological demands of early human embryogenesis.
Oocyte Ageing and Genetic Stability
The extended duration of meiotic arrest makes oocytes uniquely vulnerable to age-related changes. Over time, the structures responsible for accurate chromosomal segregation, including the meiotic spindle and cohesin proteins, become less reliable. This increases the risk of nondisjunction and aneuploidy, contributing to rising rates of infertility, pregnancy loss, and chromosomal abnormalities with advancing maternal age.
Mitochondrial ageing within the oocyte further compromises developmental potential by reducing energy availability and increasing oxidative stress. Together, these changes explain why maternal age is one of the strongest predictors of reproductive outcomes and why oocyte quality, not just quantity, declines across the reproductive lifespan.
Clinical Connections
Age-related changes in oocyte number and quality have a major impact on reproductive outcomes, even in the absence of overt disease. From the mid-30s onward, follicle loss accelerates and the risk of chromosomal errors rises as the mechanisms that maintain meiotic integrity become less reliable. This combination of declining quantity and quality explains why fertility can fall sharply despite apparently regular menstrual cycles.
In clinical practice, reduced oocyte competence often matters more than absolute follicle number. Even when ovulation occurs, ageing oocytes are more likely to exhibit aneuploidy, leading to reduced implantation rates, early pregnancy loss, or chromosomal abnormalities. The effects of disrupted oogenesis are also seen in pathological states, including premature ovarian insufficiency, where follicular depletion occurs well before the expected age, and in individuals exposed to gonadotoxic treatments or autoimmune processes. Key clinical implications of impaired oogenesis include:
Reduced fertility with advancing age, driven by declining oocyte quality rather than cycle regularity alone
Increased risk of aneuploidy and miscarriage, reflecting age-related meiotic errors
Diminished ovarian reserve, whether age-related or accelerated by medical conditions or treatments
Assisted reproductive technologies aim to overcome some of these limitations by stimulating the ovaries to produce multiple mature oocytes within a single cycle. While controlled ovarian stimulation can increase the number of secondary oocytes retrieved, it cannot reverse age-related changes in oocyte competence. Embryo quality remains closely linked to the biological age and metabolic health of the oocyte, which is why treatment success rates decline with advancing maternal age despite similar stimulation protocols.
An understanding of oogenesis also clarifies why younger individuals generally respond more favourably to fertility treatments and why elective oocyte cryopreservation is most effective when performed earlier in reproductive life. It further explains why conditions that disrupt follicular development, such as polycystic ovary syndrome, can impair oocyte maturation even when ovarian reserve appears preserved.
Concept Check
Why are primary oocytes arrested in prophase I for years, and how is this arrest maintained?
What hormonal changes trigger the primary oocyte to complete meiosis I before ovulation?
Why does oogenesis produce one functional oocyte rather than four, and what is the purpose of polar bodies?
How does maternal age influence the risk of chromosomal abnormalities in oocytes?
At what stage of meiosis is the secondary oocyte arrested, and what event triggers completion of meiosis II?